TSE:TRIL

Trillium Therapeutics Competitors

C$12.48
-0.49 (-3.78 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$12.27
Now: C$12.48
C$12.91
50-Day Range
C$12.39
MA: C$13.52
C$14.94
52-Week Range
C$5.73
Now: C$12.48
C$27.12
Volume118,609 shs
Average Volume188,771 shs
Market CapitalizationC$1.26 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Trillium Therapeutics (TSE:TRIL) Vs. CRON, CXR, APS, BU, BLU, and TH

Should you be buying TRIL stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Trillium Therapeutics, including Cronos Group (CRON), Concordia International (CXR), Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), and Theratechnologies (TH).

Cronos Group (TSE:CRON) and Trillium Therapeutics (TSE:TRIL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Cronos Group and Trillium Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group01202.67
Trillium Therapeutics0000N/A

Cronos Group presently has a consensus price target of C$9.68, suggesting a potential downside of 7.19%. Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 100.32%. Given Trillium Therapeutics' higher possible upside, analysts plainly believe Trillium Therapeutics is more favorable than Cronos Group.

Earnings and Valuation

This table compares Cronos Group and Trillium Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$46.72 million80.43C$-95,828,894.00C($0.27)-39.21
Trillium TherapeuticsC$148,000.008,492.22C$-88,422,502.00C($0.88)-14.21

Trillium Therapeutics has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cronos Group and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos GroupN/AN/AN/A
Trillium TherapeuticsN/AN/AN/A

Summary

Trillium Therapeutics beats Cronos Group on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Concordia International and Trillium Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A
Trillium TherapeuticsC$148,000.008,492.22C$-88,422,502.00C($0.88)-14.21

Concordia International has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Concordia International and Trillium Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concordia International0000N/A
Trillium Therapeutics0000N/A

Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 100.32%.

Profitability

This table compares Concordia International and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concordia InternationalN/AN/AN/A
Trillium TherapeuticsN/AN/AN/A

Summary

Concordia International beats Trillium Therapeutics on 4 of the 4 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Aptose Biosciences and Trillium Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.85)-7.58
Trillium TherapeuticsC$148,000.008,492.22C$-88,422,502.00C($0.88)-14.21

Aptose Biosciences has higher earnings, but lower revenue than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aptose Biosciences and Trillium Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Trillium Therapeutics0000N/A

Aptose Biosciences presently has a consensus price target of C$12.00, suggesting a potential upside of 87.21%. Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 100.32%. Given Trillium Therapeutics' higher probable upside, analysts plainly believe Trillium Therapeutics is more favorable than Aptose Biosciences.

Profitability

This table compares Aptose Biosciences and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Trillium TherapeuticsN/AN/AN/A

Summary

Aptose Biosciences beats Trillium Therapeutics on 3 of the 5 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Trillium Therapeutics and Burcon NutraScience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.008,492.22C$-88,422,502.00C($0.88)-14.21
Burcon NutraScienceC$12,045.0045,792.46C$107,101.00C$0.005,150.00

Burcon NutraScience has lower revenue, but higher earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Trillium Therapeutics and Burcon NutraScience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
Burcon NutraScience00103.00

Trillium Therapeutics currently has a consensus target price of C$25.00, suggesting a potential upside of 100.32%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential downside of 2.91%. Given Trillium Therapeutics' higher probable upside, research analysts clearly believe Trillium Therapeutics is more favorable than Burcon NutraScience.

Profitability

This table compares Trillium Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Summary

Burcon NutraScience beats Trillium Therapeutics on 5 of the 7 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Trillium Therapeutics and BELLUS Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.008,492.22C$-88,422,502.00C($0.88)-14.21
BELLUS HealthC$15,000.0029,872.51C$-42,145,306.00C($0.54)-10.63

BELLUS Health has lower revenue, but higher earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Trillium Therapeutics and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
BELLUS Health01202.67

Trillium Therapeutics currently has a consensus target price of C$25.00, indicating a potential upside of 100.32%. Given Trillium Therapeutics' higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than BELLUS Health.

Profitability

This table compares Trillium Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
BELLUS HealthN/AN/AN/A

Summary

BELLUS Health beats Trillium Therapeutics on 5 of the 7 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Trillium Therapeutics and Theratechnologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.008,492.22C$-88,422,502.00C($0.88)-14.21
TheratechnologiesC$66.05 million6.47C$-34,907,769.00C($0.37)-12.25

Theratechnologies has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Trillium Therapeutics and Theratechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
Theratechnologies02002.00

Trillium Therapeutics currently has a consensus target price of C$25.00, indicating a potential upside of 100.32%. Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 17.04%. Given Trillium Therapeutics' higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Theratechnologies.

Profitability

This table compares Trillium Therapeutics and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
TheratechnologiesN/AN/AN/A

Summary

Theratechnologies beats Trillium Therapeutics on 4 of the 6 factors compared between the two stocks.


Trillium Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cronos Group logo
CRON
Cronos Group
0.7$10.43-2.5%C$3.76 billionC$46.72 million-39.21
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
APS
Aptose Biosciences
1.3$6.41-7.2%C$569.75 millionN/A-7.58
BU
Burcon NutraScience
1.2$5.15-2.5%C$551.57 millionC$12,045.005,150.00
BLU
BELLUS Health
0.5$5.72-3.7%C$448.09 millionC$15,000.00-10.63
Theratechnologies logo
TH
Theratechnologies
0.7$4.52-0.4%C$427.60 millionC$66.05 million-12.25
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.28-0.9%C$401.71 millionC$76.09 million-57.54
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
MDNA
Medicenna Therapeutics
0.5$5.00-0.6%C$264.51 millionN/A-16.18
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
NEPT
Neptune Wellness Solutions
1.2$1.48-3.4%C$244.93 millionC$52.78 million-1.10
IMV logo
IMV
IMV
1.2$3.48-1.7%C$239.70 millionC$3,000.00-6.02
FRX
Fennec Pharmaceuticals
0.5$8.08-7.1%C$210.10 millionC$170,000.00-8.43Gap Down
RVX
Resverlogix
0.7$0.88-1.1%C$205.91 millionN/A80.00Gap Down
ATE
Antibe Therapeutics
1.3$4.44-2.5%C$202.05 millionC$9.33 million-5.64
ONC
Oncolytics Biotech
1.2$3.72-0.5%C$196.30 millionN/A-6.64Analyst Report
HBP
Helix BioPharma
0.5$0.90-0.0%C$127.02 millionN/A-16.36Gap Down
IPA
ImmunoPrecise Antibodies
0.4$12.56-2.8%C$123.03 millionC$17.18 million-58.69Gap Down
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.51-7.8%C$88.79 millionC$81,000.0015.00Gap Up
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.61-1.6%C$66.76 millionC$11.64 million-11.96News Coverage
Gap Down
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.33-6.1%C$58.80 millionC$123,870.00-25.38
PMN
ProMIS Neurosciences
0.5$0.19-5.4%C$56.60 millionC$1,787.00-9.25Gap Up
COV
Covalon Technologies
0.6$1.32-3.0%C$37.44 millionC$23.84 million-5.55News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.26-5.9%C$34.02 millionC$13.02 million-0.37Gap Up
IGX
IntelGenx Technologies
0.9$0.60-5.0%C$30.87 millionC$1.54 million-7.41
QPT
Quest PharmaTech
0.8$0.11-13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74-5.4%C$21.65 millionC$16.14 million22.42Gap Up
CTX
Crescita Therapeutics
0.6$0.85-1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.17-3.0%C$14.12 millionC$1.34 million-4.71Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.09-11.8%C$12.70 millionN/A-3.86High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.07-7.7%C$11.06 millionC$2.03 million-1.51
MPH
Medicure
0.7$1.61-1.9%C$10.80 millionC$12.71 million-1.04
BTI
Bioasis Technologies
0.7$0.34-13.2%C$10.16 millionC$4.12 million30.91High Trading Volume
Gap Up
HEM
Hemostemix
0.6$0.37-1.4%C$9.07 millionN/A-2.20
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.40-7.6%C$6.94 millionC$5.60 million7.31Gap Down
IOT
Innovotech
0.8$0.16-6.3%C$6.52 millionC$1.04 million80.00
BCT
BriaCell Therapeutics
0.5$4.10-2.4%C$4.48 millionN/A-1.32
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.